Company Overview and News
KUALA LUMPUR: Mah Sing Group Bhd said 74% of the residential properties it targets to sell this year are priced below RM500,000.
PETALING JAYA: Mah Sing Group Bhd has welcomed the announcement of new categories of affordable housing under the National Housing Policy, saying the group has been developing affordable homes since 2015.
KUALA LUMPUR (Oct 15): Mah Sing Group Bhd said 74% of residential properties it targets to sell this year, are priced below RM500,000.
KUALA LUMPUR, Oct 1 — Property developers will review prices of new homes in response to the government’s call for tax exemption savings on construction materials to be passed on to consumers.
KUALA LUMPUR (Oct 1): The FBM KLCI is expected to commence the final quarter of 2018 on a subdued note today as market participants await more directions from finance minister Lim Guan Eng when he tables Budget 2019 on Nov 2.
4634 5843 2127 7158 0083 5184 5268 8583 5256
KUALA LUMPUR (Sept 28): Based on corporate announcements and news flow today, companies in focus on Monday (Oct 1) may include: Notion VTec Bhd, IRIS Corp Bhd, Sapura Energy Bhd, Mah Sing Group Bhd, Scomi Group Bhd, Pos Malaysia Bhd, Reach Energy Bhd, Cypark Resources Bhd, Comfort Gloves Bhd, Gamuda Bhd, Kumpulan Perangsang Selangor Bhd (KPS), Berjaya Corp Bhd (BCorp), My EG Services Bhd (MyEG) and Ikhmas Jaya Group Bhd.
4634 5843 2127 7158 0083 5184 5268 8583 5256
ISKANDAR PUTERI: Mah Sing Group Bhd has inked a memorandum of understanding (MoU) with the Netherlands Maritime Institute of Technology (NMIT) to provide fully-furnished accommodation for the institute’s students.
ISKANDAR PUTERI (Sept 20): Mah Sing Group Bhd has inked a memorandum of understanding (MoU) with the Netherlands Maritime Institute of Technology (NMIT) to provide fully-furnished accommodation for the institute's students.
THE property development sector, while remaining cautious, has generally been more positive since the new government took office. The government has plans to announce a new national housing policy, and to set up a single entity to address affordable housing.
In a filing with Bursa Malaysia yesterday, the property developer said its net profit for the six-months period ended June 30, 2018 stood at RM141.33mil compared with RM180.811mil in the previous corresponding period, while revenue in the first half of its financial year stood at RM1.17bil compared with RM1.45bil a year earlier.
BSMAF 8583 1818
KUALA LUMPUR (Aug 30): Mah Sing Group Bhd, which recorded a net profit of RM77.1 million in its second quarter, has secured new property sales amounting to RM942.1 million in the first half of its financial year 2018 (1HFY18) and is confident of attaining its minimum sales target of RM1.8 billion for the full year.
JUST before May 9, a prominent personality tried to take over a 120-acre tract in Kuala Lumpur that was owned by the government. After much consultation, it was decided that the deal would be deferred until after the general election to avoid controversy.
7889 3905 8583 4022
AFTER three years of staying below the radar following an appeal that ordered the Penang-based property developer to stop construction work on its maiden project in Bandar Tanjong Pinang, Penang, Ewein Bhd is all set to make a comeback.
PBLOF 5148 8664 1295 8583
ISKANDAR PUTERI: i2M Ventures Sdn Bhd (i2M), a wholly-owned subsidiary of Khazanah Nasional Bhd, has signed a strategic partnership with Mah Sing Group Bhd to provide accommodations to companies operating in Medini Iskandar, Johor.
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...